Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…